First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration
Analysis of first-year real-world outcomes after switching to brolucizumab in nAMD patients refractory to other anti-VEGF agents showed improved anatomic outcomes, limited functional improvement and low incidence of IOI-related adverse events.
Authors
- Jeong Hyun Lee (ORCID: https://orcid.org/0000-0002-4859-7534)
- Joo Young Shin (ORCID: https://orcid.org/0000-0001-5062-6392)
- Jeeyun Ahn (ORCID: https://orcid.org/0000-0001-9017-1652)
Institutions
- Seoul National University (KR)
- Seoul Metropolitan Government (KR)
- SNUH SMG-SNU Boramae Medical Center (KR)
Publication Details
- Journal
- Japanese Journal of Ophthalmology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1007/s10384-024-01134-7
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Seoul National University
- Seoul National University Hospital